A Phase II Safety and Efficacy Study of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Patients with Metastatic Urothelial Cancer

R. Pili, R. Qin, P.J. Flynn, J. Picas, Michael Millward, W.M. Ho, H. Pitot, W. Tan, K.M. Miles, C. Erlichman, U. Vaishampayan

    Research output: Contribution to journalArticlepeer-review

    54 Citations (Scopus)
    Original languageEnglish
    Pages (from-to)477-88
    JournalClinical Genitourinary Cancer
    Issue number4
    Publication statusPublished - 2014

    Cite this